Payam Nahid

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis
    Payam Nahid
    Pulmonary and Critical Care Medicine, University of California, San Francisco at San Francisco General Hospital, 1001 Potrero Ave, 5K1, San Francisco, CA 94110, USA Electronic address
    Tuberculosis (Edinb) 94:187-96. 2014
  2. doi request reprint Update in tuberculosis and nontuberculous mycobacterial disease 2011
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine and Curry International Tuberculosis Center, University of California, San Francisco at San Francisco General Hospital, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 185:1266-70. 2012
  3. pmc Clinical research and development of tuberculosis diagnostics: moving from silos to synergy
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine, Department of Medicine at San Francisco General Hospital and Curry International Tuberculosis Center, University of California, San Francisco, CA 94110, USA
    J Infect Dis 205:S159-68. 2012
  4. pmc Racial differences in tuberculosis infection in United States communities: the coronary artery risk development in young adults study
    Payam Nahid
    Curry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    Clin Infect Dis 53:291-4. 2011
  5. pmc CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
    Payam Nahid
    Division of Pulmonary and Critical Care, Curry International Tuberculosis Center, San Francisco General Hospital, University of California San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 184:972-9. 2011
  6. pmc Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis
    Payam Nahid
    Curry International Tuberculosis Center, University of California, San Francisco, CA, USA
    BMC Infect Dis 11:1. 2011
  7. pmc Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine, Francis J Curry National Tuberculosis Center, San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 5:e10753. 2010
  8. pmc Treatment outcomes of patients with HIV and tuberculosis
    Payam Nahid
    University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, 5K1, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 175:1199-206. 2007
  9. pmc Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis
    Adithya Cattamanchi
    Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco GeneralHospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
    Clin Infect Dis 48:179-85. 2009
  10. pmc Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis
    David J Horne
    Division of Pulmonary and Critical Care Medicine, Seattle, WA 98104, USA
    Lancet Infect Dis 10:387-94. 2010

Detail Information

Publications24

  1. pmc Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis
    Payam Nahid
    Pulmonary and Critical Care Medicine, University of California, San Francisco at San Francisco General Hospital, 1001 Potrero Ave, 5K1, San Francisco, CA 94110, USA Electronic address
    Tuberculosis (Edinb) 94:187-96. 2014
    ..The identification of accurate, quantitative, non-culture based markers of treatment response would improve the efficiency of Phase 2 TB drug testing...
  2. doi request reprint Update in tuberculosis and nontuberculous mycobacterial disease 2011
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine and Curry International Tuberculosis Center, University of California, San Francisco at San Francisco General Hospital, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 185:1266-70. 2012
    ..Advances in understanding TB epidemiology diagnosis and treatment in 2011, many of which were reported in the Journal, provide hope that the annual decline in TB cases will accelerate...
  3. pmc Clinical research and development of tuberculosis diagnostics: moving from silos to synergy
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine, Department of Medicine at San Francisco General Hospital and Curry International Tuberculosis Center, University of California, San Francisco, CA 94110, USA
    J Infect Dis 205:S159-68. 2012
    ....
  4. pmc Racial differences in tuberculosis infection in United States communities: the coronary artery risk development in young adults study
    Payam Nahid
    Curry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    Clin Infect Dis 53:291-4. 2011
    ..0; 95% confidence interval, 1.5-2.9)...
  5. pmc CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
    Payam Nahid
    Division of Pulmonary and Critical Care, Curry International Tuberculosis Center, San Francisco General Hospital, University of California San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 184:972-9. 2011
    ..This article summarizes these recommendations and provides a roadmap for their implementation...
  6. pmc Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis
    Payam Nahid
    Curry International Tuberculosis Center, University of California, San Francisco, CA, USA
    BMC Infect Dis 11:1. 2011
    ..Tuberculosis is a leading cause of death worldwide, yet the determinants of death are not well understood. We sought to determine risk factors for mortality during treatment of drug-susceptible pulmonary tuberculosis under program settings...
  7. pmc Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine, Francis J Curry National Tuberculosis Center, San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 5:e10753. 2010
    ..Disease presentation and response to drug treatment varied by lineage, but these associations were no longer statistically significant after adjustment for other variables associated with week-8 culture status...
  8. pmc Treatment outcomes of patients with HIV and tuberculosis
    Payam Nahid
    University of California, San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, 5K1, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 175:1199-206. 2007
    ..The optimal length of tuberculosis treatment in patients coinfected with HIV is unknown...
  9. pmc Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis
    Adithya Cattamanchi
    Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco GeneralHospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
    Clin Infect Dis 48:179-85. 2009
    ..Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described...
  10. pmc Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis
    David J Horne
    Division of Pulmonary and Critical Care Medicine, Seattle, WA 98104, USA
    Lancet Infect Dis 10:387-94. 2010
    ..Although we pooled a diverse group of patients, the individual studies had similar performance characteristics. Better predictive markers are needed...
  11. ncbi request reprint Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response
    Amador Goodridge
    Division of Infectious Diseases and Vaccinology, School of Public Health, 201 Hildebrand Hall, University of California, Berkeley, CA 94720, USA
    Tuberculosis (Edinb) 92:243-7. 2012
    ..The measurement of IgM anti-phospholipid antibodies may be a useful biomarker to monitor treatment response in non-cavitary TB patients...
  12. pmc Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis
    Raymund Dantes
    Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e37956. 2012
    ..Specific isoniazid (INH) resistance conferring mutations have been shown to impact the likelihood of tuberculosis (TB) transmission. However, their role in the clinical presentation and outcomes of TB has not been evaluated...
  13. doi request reprint Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective
    Nicholas D Walter
    Division of Pulmonary and Critical Care, San Francisco General Hospital, University of California, San Francisco, 94110, USA
    Clin Infect Dis 46:103-6. 2008
    ..We report that 62% of these cases were not preventable and conclude that a further reduction in the incidence of tuberculosis among foreign-born persons will be modest without modification of current guidelines...
  14. doi request reprint Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection
    Adithya Cattamanchi
    University of California San Francisco, San Francisco General Hospital, San Francisco, CA 94110, USA
    Chest 133:875-80. 2008
    ..In patients with HIV infection, the radiographic findings of M kansasii lung disease are not well described...
  15. pmc Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects
    John Z Metcalfe
    San Francisco General Hospital, University of California, 94110 0111, USA
    Am J Respir Crit Care Med 181:87-93. 2010
    ..The contribution of interferon-gamma release assays (IGRAs) to appropriate risk stratification of active tuberculosis suspects has not been studied...
  16. pmc Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV
    Christina Yoon
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Curry International Tuberculosis Center, and HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda Department of Epidemiology and Biostatistics, University of California, San Francisco, CA Department of Internal Medicine, University of California, San Francisco, CA Center for Global Health, Massachusetts General Hospital, Harvard Medical School, Boston, MA Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Boston, MA and Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 65:551-6. 2014
    ..We evaluated whether testing for C-reactive protein (CRP) improves patient selection for IPT...
  17. ncbi request reprint Prevention of tuberculosis in HIV-infected patients
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco General Hospital, San Francisco, CA, USA
    Curr Opin Infect Dis 19:189-93. 2006
    ..In order to control tuberculosis in areas with high rates of co-infection, strategies must be developed to prevent tuberculosis in HIV-infected individuals...
  18. pmc Novel hot spot of IS6110 insertion in Mycobacterium tuberculosis
    Elizabeth Y Kim
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, San Francisco General Hospital, Francis J Curry National Tuberculosis Center, University of California, San Francisco, California, USA
    J Clin Microbiol 48:1422-4. 2010
    ..Because RD724 defines sublineage 724 of M. tuberculosis, caution must be exercised when screening for RD724, as different polymorphisms can be observed in this region...
  19. pmc Advances in the diagnosis and treatment of tuberculosis
    Payam Nahid
    Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, 1001 Potrero Avenue, Room 5K1, San Francisco, CA 94110, USA
    Proc Am Thorac Soc 3:103-10. 2006
    ....
  20. pmc Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples
    Adeline Nyamathi
    Audrienne H Moseley Endowed Chair in Community Health Research, School of Nursing, University of California, Los Angeles, CA 90095 1702, USA
    Nurs Res 57:33-9. 2008
    ....
  21. pmc Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California
    Jonathan M Budzik
    Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 9:e95645. 2014
    ..PZA is also considered a potent companion drug for newer regimens under development. There are limited data on the demographic, clinical, and pathogen characteristics of PZA resistant tuberculosis...
  22. pmc Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis
    Karen R Steingart
    Francis J Curry National Tuberculosis Center, University of California, San Francisco, 3180 18th Street, Suite 101, San Francisco, CA 94110 2028, USA
    Clin Vaccine Immunol 16:260-76. 2009
    ..The use of a case-control design with healthy controls for the majority of studies was a limitation of the review. Efforts are needed to improve the methodological quality of tuberculosis diagnostic studies...
  23. ncbi request reprint Clinical practice. Latent tuberculosis infection
    Robert M Jasmer
    Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA
    N Engl J Med 347:1860-6. 2002
  24. pmc Childhood tuberculosis in northern Viet Nam: a review of 103 cases
    Robert J Blount
    Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 9:e97267. 2014
    ..Childhood tuberculosis causes significant morbidity and mortality in Southeast Asia, yet little is known about the epidemiology and clinical characteristics of this disease in Viet Nam...

Research Grants2

  1. Interplay of strain and ethnicity in the immune response to M. tuberculosis
    Payam Nahid; Fiscal Year: 2007
    ..Neil Risch) and epidemiology (Drs. Dennis Osmond and Neil Risch). Together, these senior investigators represent the diversity of fields that are essential for my training and proposed research study. ..